HIV-1-infected patients with envelope-specific lymphoproliferation or long-term nonprogression lack antibodies suppressing glycoprotein 120 antigen presentation

Journal of Infectious Diseases

Volumn 189, Issue 5, 2004, Pages 852-861

  Chien Jr , Peter C ^a,b   Chen, Daniel ^a,b   Chen, Pei De ^a,b   Tuen, Michael ^a,b   Cohen, Sandra ^a,b   Migueles, Stephen A ^c   Connors, Mark ^c   Rosenberg, Eric ^d   Malhotra, Uma ^e   Gonzalez, Charles ^a   Hioe, Catarina E ^a,b,f  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G;

ANTIGEN BINDING; ANTIGEN PRESENTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; VIRUS ENVELOPE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIGENS, CD4; BINDING SITES; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HUMANS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 12144290267     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/380133     Document Type: Article

References (35)

1. + T cell-proliferative responses to glycoprotein 120. AIDS Res Hum Retroviruses 2000; 16:893-905.
2. Hioe CE, Tuen M, Chien PC Jr, et al. Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120. J Virol 2001; 75:10950-7.
3. Kwong PD, Doyle ML, Casper DJ, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002; 420:678-82.
4. Chien PC Jr, Cohen S, Kleeberger C, et al. High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 glycoprotein 120 are associated with faster disease progression. J Infect Dis 2002; 186:205-13.
5. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000; 97: 2709-14.
6. + T cells. Immunol Lett 2001; 79:141-50.
7. + T cell proliferation is coupled to perform expression and is maintained in nonprogressors. Nat Immunol 2002; 3:1061-8.
8. Cecilia D, Kleeberger C, Munoz A, Giorgi JV, Zolla-Pazner S. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis 1999; 179:1365-74.
9. + T cells specific for HIV type 1 envelope gp120 from chronically HIV type 1-infected subjects, AIDS Res Hum Retroviruses 2003; 19:793-806.
10. Cavacini LA, Emes CL, Power J, et al. Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression. J Acquir Immune Defic Syndr 1993; 6:1093-102.
11. Turbica I, Simon F, Besnier JM, et al. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection. J Med Virol 1997; 52:309-15.
12. + lymphocyte number, and AIDS-free time. J Infect Dis 1992; 166:1217-22.
13. Cheingsong-Popov R, Panagiotidi C, Bowcock S, Aronstam A, Wadsworth J, Weber J. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. BMJ 1991; 302:23-6.
14. Hogervorst E, Jurriaans S, de Wolf F, et al. Predictors for non-and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 1995; 171:811-21.
15. Weber JN, Clapham PR, Weiss RA, et al. Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis. Lancet 1987; 1:119-22.
16. Loomis-Price LD, Cox JH, Mascola JR, et al. Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. J Infect Dis 1998; 178:1306-16.
17. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-6.
18. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999; 5:518-25.
19. Malhotra U, Holte S, Zhu T, et al. Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection. J Virol 2003; 77:2663-74.
20. Karwowska S, Gorny MK, Buchbinder A, et al. Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res Hum Retroviruses 1992; 8:1099-106.
21. Moore JP, McCutchan FE, Poon SW, et al. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 1994; 68:8350-64.
22. Learmont JC, Geczy AF, Mills J, et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1: a report from the Sydney Blood Bank Cohort. N Engl J Med 1999; 340: 1715-22.
23. Michael NL. Host genetic influences on HIV-1 pathogenesis. Curr Opin Immunol 1999; 11:466-74.
24. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405-11.
25. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996; 271: 324-8.
26. + T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity. Hum Immunol 2001; 62:561-76.
27. + T cell responses associated with control of viremia. Science 1997; 278:1447-50.
28. Kessler JA 2nd, McKenna PM, Emini EA, et al. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses 1997; 13:575-82.
29. Hioe CE, Xu S, Chigurupati P, et al. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int Immunol 1997; 9:1281-90.
30. Posner MR, Cavacini LA, Emes CL, Power J, Byrn R. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J Acquir Immune Defic Syndr 1993; 6:7-14.
31. Barbas CF 3rd, Bjorling E, Chiodi F, et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1992; 89:9339-43.
32. + T cells. Nature 2002; 417:95-8.
33. Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA. Glycosylation and the immune system. Science 2001; 291:2370-6.
34. + T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc Natl Acad Sci USA 2001; 98:4587-92.
35. Botarelli P, Houlden BA, Haigwood NL, Servis C, Montagna D, Abrignani S. N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes. J Immunol 1991; 147:3128-32.